IMUGENE LIMITED — Capital/Financing Update 2025

Jan 28, 2025

==> picture [177 x 31] intentionally omitted <==

ASX Announcement

Imugene receives A$20 million for convertible notes issue

SYDNEY, Australia, 29 January 2025: Imugene Limited (ASX:IMU), a clinical-stage immuno-oncology company, is pleased to announce that it has received A$20 million from the issuance of senior, unsecured, zero-coupon convertible notes to CVI Investments, Inc.

This funding represents the first tranche of a total A$46 million capital raising announced on 23 December 2024, comprising convertible notes and associated unlisted warrants. The proceeds from this initial tranche will be directed toward advancing Imugene’s immuno-oncology clinical trial pipeline, including azer-cel, onCARlytics, and VAXINIA programs.

The convertible notes, with a five-year maturity, provide significant flexibility for Imugene, with no interest costs and potential semi-annual conversion to ordinary shares at a premium to the Company’s market price.

For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

info@imugene.com

General Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

Matt Wright matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited Follow us on Twitter @TeamImugene Watch us on YouTube @ImugeneLimited

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

==> picture [42 x 42] intentionally omitted <==

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.

IMUGENE LIMITED ACN 009 179 551

2